Overview

* Viemed Q3 revenue rises 24% yr/yr to $71.9 mln

* Adjusted EBITDA for Q3 rises 15.5% yr/yr to $16.1 mln

* Company repurchased 1.7 mln shares for $11.4 mln, enhancing shareholder value

Outlook

* Viemed updates full-year revenue guidance to $271 mln-$273 mln

* Company raises full-year adjusted EBITDA guidance to $60 mln-$62 mln

Result Drivers

* LEHANS ACQUISITION - Strategic acquisition of Lehans Medical Equipment was immediately accretive to net income and EPS

* PATIENT BASE EXPANSION - Co increased ventilator and PAP therapy patient counts significantly, contributing to revenue growth

* SHARE REPURCHASE - Completion of share repurchase program enhanced EPS and demonstrated disciplined capital deployment

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Slight $71.91 $72 mln

Revenue Miss* mln (1

Analyst)

Q3 Gross $41.35

Profit mln

Q3 $5.64

Income mln

from

Operatio

ns

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Viemed Healthcare Inc ( VMD ) is $13.00, about 49.7% above its November 4 closing price of $6.54

* The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)